


o o o o v e s c o
innovation in scope

one & done

OTSC[®] – The first choice: highest efficacy in GI bleeding.



Proven clinical benefit*
www.ovesco.com



OTSC[®]
SYSTEM



Proven clinical benefit:

OTSC® in first-line therapy significantly reduces re-bleeding risk and bleeding associated mortality in UGIB (FLETRock evaluation¹).

Compared to Rockall's validated prediction, re-bleeding risk and bleeding related mortality were significantly reduced from 53.2 % to 21.4 % ($p < 0.001$) and 27.9 % to 10.9 % ($p = 0.011$), respectively in high-risk Rockall score (score 8) patients treated with the OTSC.

OTSC® significantly improves outcome of hemostasis in patients randomized to OTSC® or standard therapy (STING trial²).

Successful hemostasis was achieved in 93.8 % vs 56.3 % ($p < 0.001$) of otherwise unsuccessfully treated patients, now receiving either OTSC or injection plus other clips or thermal coagulation.

1 Wedi et al. (2017), **Multicenter evaluation of first-line endoscopic treatment with the OTSC in acute non-variceal upper gastrointestinal bleeding and comparison with the Rockall cohort: the FLETRock study.**

Surgical Endoscopy, doi:10.1007/s00464-017-5678-7.

2 Schmidt A. et al. (2017), **Over-the-scope-clips versus standard endoscopic therapy in patients with recurrent peptic ulcer bleeding – a prospective randomized, multi-center trial (STING).**

Digestive Disease Week®, Chicago, IL, May 6 - 9, 2017.

OTSC® is a registered brand of Ovesco Endoscopy AG.



Download link to the symposium presentations at DGE-BV 2017.
Further information available at www.ovesco.com